Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Schlom Website

Jeffrey Schlom, Ph.D.

Selected Publications

1)  Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta R, Costarelli L, Litzinger M, Hamilton DH, Huang B, Tucker JA, Tsang KY, Schlom J, Palena C.
Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.
Clin Cancer Res. 18: 3868-79, 2012.
2)  Jochems C, Tucker JA, Vergati M, Boyerinas B, Gulley JL, Schlom J, Tsang KY.
Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.
Cancer Immunol. Immunother. 2013.
3)  Gulley JL, Madan RA, Tsang KY, Jochems C, Marte JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, Heery CR, Schlom J.
Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.
Cancer Immunol Res. 2: 133-141, 2013.
Full Text Article. [Journal]
4)  Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.
A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates.
Cancer Immunol. Immunother. 63: 407-18, 2014.
5)  Schlom J.
Therapeutic cancer vaccines: current status and moving forward.
J. Natl. Cancer Inst. 104: 599-613, 2012.
6)  Fallon J, Tighe R, Kradjian G, Guzman W, Bernhardt A, Neuteboom B, Lan Y, Sabzevari H, Schlom J, Greiner JW.
The immunocytokine NHS-IL12 as a potential cancer therapeutic.
Oncotarget. 2014.
7)  Ardiani A, Gameiro SR, Palena C, Hamilton DH, Kwilas A, King TH, Schlom J, Hodge JW.
Vaccine-Mediated Immunotherapy Directed against a Transcription Factor Driving the Metastatic Process.
Cancer Res. 74: 1945-57, 2014.
8)  Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR.
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
J. Clin. Oncol. 28: 1099-105, 2010.
9)  Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, Cereda V, Vergati M, Steinberg SM, Halabi S, Jones E, Chen C, Parnes H, Wright JJ, Dahut WL, Schlom J.
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
Cancer Immunol. Immunother. 59: 663-74, 2010.
10)  Roselli M, Cereda V, di Bari MG, Formica V, Spila A, Jochems C, Farsaci B, Donahue R, Gulley JL, Schlom J, Guadagni F.
Effects of conventional therapeutic interventions on the number and function of regulatory T cells.
Oncoimmunology. 2: e27025, 2013.
11)  Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Lancet Oncol. 13: 501-8, 2012.
12)  Vergati M, Cereda V, Madan RA, Gulley JL, Huen NY, Rogers CJ, Hance KW, Arlen PM, Schlom J, Tsang KY.
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.
Cancer Immunol. Immunother. 60: 197-206, 2011.
13)  Farsaci B, Jochems C, Grenga I, Donahue RN, Tucker JA, Pinto PA, Merino MJ, Heery CR, Madan RA, Gulley JL, Schlom J.
Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.
Int. J. Cancer. 2014.
14)  Kim PS, Jochems C, Grenga I, Donahue RN, Tsang KY, Gulley JL, Schlom J, Farsaci B.
Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Immunotherapy.
J. Immunol. 192: 2622-33, 2014.
15)  Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tsang KY, Tucker JA, Jochems C, Schlom J, Gulley JL, Madan RA.
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
Cancer Immunol. Immunother. 63: 225-34, 2014.
16)  Schlom J, Hodge JW, Palena C, Greiner JW, Tsang K, Farsaci B, Madan RA, Gulley JL.
Prendergast G, Jaffee E, eds.
Recombinant TRICOM-based therapeutic cancer vaccines (Chapter 20). In: Cancer Immunotherapy: Immune Suppression and Tumor Growth, 2nd Edition.
San Diego: Elsevier; 2013. p. 309-332 [Book Chapter]
17)  Schlom J, Palena C, Gulley JL, Greiner JW, Tsang K, Madan RA, Hodge JW.
Lattime E, Gerson S, eds.
The use of T-cell costimulation to enhance the immunogenicity of tumors (Chapter 22). In: Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation, 3rd Edition.
Waltham, MA: Elsevier; 2013. p. 315-334 [Book Chapter]
18)  Madan RA, Tsang KY, Bilusic M, Vergati M, Poole DJ, Jochems C, Tucker JA, Schlom J, Giaccone G, Gulley JL.
Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.
Oncologist. 18: 821-2, 2013.
19)  Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, Ardiani A, Apelian D, Schlom J, Palena C.
Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.
Oncotarget. 4: 1777-90, 2013.
20)  Takai S, Schlom J, Tucker J, Tsang KY, Greiner JW.
Inhibition of TGF-ß1 Signaling Promotes Central Memory T Cell Differentiation.
J. Immunol. 2013.
21)  Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA.
Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.
Cancer Immunol. Immunother. 2013.
22)  Schlom J.
Recombinant cancer vaccines and new vaccine targets.
Expert Rev Vaccines. 12: 1121-4, 2013.
23)  Campbell CT, Gulley JL, Oyelaran O, Hodge JW, Schlom J, Gildersleeve JC.
Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF.
Clin. Cancer Res. 19: 1290-9, 2013.
24)  Huang J, Jochems C, Anderson AM, Talaie T, Jales A, Madan RA, Hodge JW, Tsang KY, Liewehr DJ, Steinberg SM, Gulley JL, Schlom J.
Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity.
J. Immunol. 190: 6250-8, 2013.
25)  Schlom J, Jochems C, Gulley JL, Huang J.
The role of soluble CD40L in immunosuppression.
Oncoimmunology. 2: e22546, 2013.
26)  Huen N, Pang AL, Tucker JA, Lee T, Vergati M, Jochems C, Intrivici C, Cereda V, Chan W, Rennert OM, Madan RA, Gulley JL, Schlom J, Tsang KY.
Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer.
Int. J. Cancer. [Epub ahead of print], 2013.
27)  Bot A, Ahn M, Bosch M, Brockstedt D, Butterfield LH, Cornforth A, Harrop R, Kast WM, Koya R, Marincola F, Margolin K, McCoy C, Pawelec G, Rothman J, Ramirez-Montagut T, Schlom J, Srivastava P, Wallis S, Walter S, Wang E, Waslif J.
A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies.
J Transl Med. 10: 218, 2012.
28)  Madan RA, Bilusic M, Heery C, Schlom J, Gulley JL.
Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines.
Semin. Oncol. 39: 296-304, 2012.
29)  Takai S, Sabzevari H, Farsaci B, Schlom J, Greiner JW.
Distinct Effects of Saracatinib on Memory CD8+ T Cell Differentiation.
J. Immunol. 188: 4323-33, 2012.
30)  Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL, Schlom J.
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.
Blood. 120: 3030-8, 2012.
31)  Tucker JA, Jochems C, Gulley JL, Schlom J, Tsang KY.
Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.
Cancers (Basel). 4: 1333-48, 2012.
32)  Schlom J, Hodge JW.
Introduction: therapeutic cancer vaccines.
Semin. Oncol. 39: 243-4, 2012.
33)  Kamrava M, Kesarwala AH, Madan RA, Lita E, Kaushal A, Tsang K, Poole DJ, Steinberg SM, Ferrara T, Dahut W, Schlom J, Gulley JL.
Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy.
Prostate Cancer Prostatic Dis. 15: 289-95, 2012.
34)  Gulley JL, Leitman SF, Dahut W, Schlom J.
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
J. Natl. Cancer Inst. 104: 1106; author reply 1109-12, 2012.
35)  Schlom J.
Recent advances in therapeutic cancer vaccines.
Cancer Biother. Radiopharm. 27: 2-5, 2012.
36)  Tucker J, Jochems C, Gulley J, Schlom J, Tsang K.
Shifting the balance of cell-mediated immunity and suppression in human prostate cancer [review].
Cancers. 4: 1333-1348, 2012.
37)  Gulley JL, Madan RA, Tsang KY, Arlen PM, Camphausen K, Mohebtash M, Kamrava M, Schlom J, Citrin D.
A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.
Expert Opin Biol Ther. 11: 1409-18, 2011.
38)  Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL.
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.
Clin. Cancer Res. 17: 7164-73, 2011.
39)  Smith HA, Maricque BB, Eberhardt J, Petersen B, Gulley JL, Schlom J, McNeel DG.
IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy.
J. Biomed. Biotechnol. 2011: 454861, 2011.
40)  Gulley JL, Madan RA, Schlom J.
Impact of tumour volume on the potential efficacy of therapeutic vaccines.
Curr Oncol. 18: e150-7, 2011.
41)  Heffernan MJ, Zaharoff DA, Fallon JK, Schlom J, Greiner JW.
In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines.
Biomaterials. 32: 926-32, 2011.
42)  Cereda V, Vergati M, Huen N, di Bari MG, Jochems C, Intrivici C, Gulley JL, Apelian D, Schlom J, Tsang KY.
Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-specific effectors to regulatory T cells.
Vaccine. 29: 4992-9, 2011.
43)  Palena C, Fernando RI, Litzinger MT, Hamilton DH, Huang B, Schlom J.
Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells.
Exp. Biol. Med. (Maywood). 236: 537-45, 2011.
44)  Vergati M, Schlom J, Tsang KY.
The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring.
J. Biomed. Biotechnol. 2011: 182413, 2011.
45)  Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, Ning YM, Arlen PM, Price D, Bates SE, Fojo T.
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.
Clin. Cancer Res. 17: 907-17, 2011.
46)  Jochems C, Schlom J.
Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity.
Exp. Biol. Med. (Maywood). 236: 567-79, 2011.
47)  Larocca C, Schlom J.
Viral vector-based therapeutic cancer vaccines.
Cancer J. 17: 359-71, 2011.
48)  Gulley J, Arlen P, Hodge J, Schlom J.
Hong W, eds.
Vaccines and Immunostimulants, Chapter 57. In: Cancer Medicine 8.
Shelton, CT: PMPH-USA, Ltd; 2010. p. 725-736 [Book Chapter]
49)  Madan R, Gulley J, Celestin J, Arlen P, Schlom J.
Figg W, Chau C, Small E, eds.
Cancer immunology, immunotherapeutics and vaccine approaches. In: Drug Management of Prostate Cancer.
New York: Springer; 2010. p. 305-319 [Book Chapter]
50)  Nesslinger NJ, Ng A, Tsang KY, Ferrara T, Schlom J, Gulley JL, Nelson BH.
A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.
Clin. Cancer Res. 16: 4046-56, 2010.
51)  Litzinger MT, Foon KA, Tsang K, Schlom J, Palena C.
Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.
Leuk Res. 34: 1351-7, 2010.
52)  Boehm AL, Higgins J, Franzusoff A, Schlom J, Hodge JW.
Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations.
Cancer Immunol. Immunother. 59: 397-408, 2010.
53)  Farsaci B, Sabzevari H, Higgins JP, Di Bari MG, Takai S, Schlom J, Hodge JW.
Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.
Int J Cancer. 127: 1603-13, 2010.
54)  Zaharoff DA, Hance KW, Rogers CJ, Schlom J, Greiner JW.
Intratumoral Immunotherapy of Established Solid Tumors With Chitosan/IL-12.
J Immunther. 33: 697-705, 2010.
55)  Masuelli L, Marzocchella L, Focaccetti C, Lista F, Nardi A, Scardino A, Mattei M, Turriziani M, Modesti M, Forni G, Schlom J, Modesti A, Bei R.
Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice.
Cancer Immunol Immunother. 59: 1247-58, 2010.
56)  Cereda V, Poole DJ, Palena C, Das S, Bera TK, Remondo C, Gulley JL, Arlen PM, Yokokawa J, Pastan I, Schlom J, Tsang KY.
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
Cancer Immunol. Immunother. 59: 63-71, 2010.
57)  Vergati M, Intrivici C, Huen N, Schlom J, Tsang K.
Strategies for cancer vaccine development.
J Biomed Biotech. 2010: 596432, 2010.
58)  Schlom J.
The MUC1-C oncoprotein as a target in hematologic malignancies.
Cancer Biol. Ther. 10: 492-4, 2010.
59)  Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C.
The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells.
J. Clin. Invest. 120: 533-44, 2010.
60)  Madan RA, Mohebtash M, Schlom J, Gulley JL.
Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design.
Expert Opin. Biol. Ther. 10: 19-28, 2010.
61)  Palena C, Schlom J.
Vaccines against human carcinomas: strategies to improve antitumor immune responses.
J. Biomed. Biotechnol. 2010: 380697, 2010.
62)  Rotow J, Gameiro SR, Madan RA, Gulley JL, Schlom J, Hodge JW.
Vaccines as monotherapy and in combination therapy for prostate cancer.
Clin Transl Sci. 3: 116-22, 2010.
63)  Schlom J, Lowy D, Schiller J.
Sanders S, eds.
The interface of cancer and HIV/AIDS vaccines: both preventive and therapeutic. In: From Cause to Care: Commemorating 25 years of HIV/AIDS research.
.: Science Collections; 2009. p. 41-3 [Book Chapter]
64)  Yang S, Schlom J.
Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8(+) T cells.
Cancer Immunol. Immunother. 58: 503-515, 2009.
65)  Litzinger MT, Foon KA, Sabzevari H, Tsang K, Schlom J, Palena C.
Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients.
Cancer Immunol. Immunother. 58: 955-65, 2009.
66)  Hodge J, Higgins J, Schlom J.
Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
Vaccine. 27: 4475-82, 2009.
67)  Remondo C, Cereda V, Mostböck S, Sabzevari H, Franzusoff A, Schlom J, Tsang KY.
Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen.
Vaccine. 27: 987-94, 2009.
68)  Zaharoff DA, Hoffman BS, Hooper HB, Benjamin Jr CJ, Khurana KK, Hance KW, Rogers CJ, Pinto PA, Schlom J, Greiner JW.
Intravesical immunotherapy of superficial bladder cancer with chitosan/IL-12.
Cancer Res. 69: 6192-9, 2009.
69)  di Bari MG, Lutsiak ME, Takai S, Mostböck S, Farsaci B, Tolouei Semnani R, Wakefield LM, Schlom J, Sabzevari H.
TGF-beta modulates the functionality of tumor-infiltrating CD8(+) T cells through effects on TCR signaling and Spred1 expression.
Cancer Immunol. Immunother. 58: 1809-1818, 2009.
70)  Hance KW, Rogers CJ, Zaharoff DA, Canter D, Schlom J, Greiner JW.
The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.
Clin. Cancer Res. 15: 2387-96, 2009.
71)  Madan RA, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, Arlen PM.
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
Clin. Cancer Res. 14: 4526-31, 2008.
72)  Garnett CT, Schlom J, Hodge JW.
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement.
Clin. Cancer Res. 14: 3536-44, 2008.
73)  Yokokawa J, Cereda V, Remondo C, Gulley JL, Arlen PM, Schlom J, Tsang KY.
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.
Clin. Cancer Res. 14: 1032-40, 2008.
74)  Rogers C, Zaharoff D, Hance K, Perkins S, Hursting S, Schlom J, Greiner J.
Exercise enhances vaccine induced antigen specific T cell responses.
Vaccine. 5407-5415, 2008.
75)  Mostbock S, Lutsiak ME, Milenic DE, Baidoo K, Schlom J, Sabzevari H.
IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8(+) T cell responses and increases the ratio of effector/memory CD8(+) T cells to regulatory T cells.
J. Immunol. 180: 5118-29, 2008.
76)  Schlom J, Gulley JL, Arlen PM.
Paradigm shifts in cancer vaccine therapy.
Exp. Biol. Med. 233: 522-34, 2008.
77)  Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, Remondo C, Cereda V, Jones JL, Pazdur MP, Higgins JP, Hodge JW, Steinberg SM, Kotz H, Dahut WL, Schlom J.
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
Clin. Cancer Res. 14: 3060-9, 2008.
78)  Bernstein MB, Chakraborty M, Wansley EK, Guo Z, Franzusoff A, Mostbock S, Sabzevari H, Schlom J, Hodge JW.
Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells.
Vaccine. 26: 509-21, 2008.
79)  Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, Gulley JL.
Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant.
Clin. Cancer Res. 14: 5284-5291, 2008.
80)  Chakraborty M, Wansley EK, Carrasquillo JA, Yu S, Paik CH, Camphausen K, Becker MD, Goeckeler WF, Schlom J, Hodge JW.
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.
Clin. Cancer Res. 14: 4241-9, 2008.
81)  Cheever MA, Schlom J, Weiner LM, Lyerly HK, Disis ML, Greenwood A, Grad O, Nelson WG.
Translational Research Working Group developmental pathway for immune response modifiers.
Clin. Cancer Res. 14: 5692-9, 2008.
82)  Lutsiak ME, Tagaya Y, Adams AJ, Schlom J, Sabzevari H.
Tumor-Induced Impairment of TCR Signaling Results in Compromised Functionality of Tumor-Infiltrating Regulatory T Cells.
J. Immunol. 180: 5871-81, 2008.
83)  Chakraborty M, Gelbard A, Carrasquillo JA, Yu S, Mamede M, Paik CH, Camphausen K, Schlom J, Hodge JW.
Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects.
Cancer Immunol. Immunother. 57: 1173-83, 2008.
84)  Wansley EK, Chakraborty M, Hance KW, Bernstein MB, Boehm AL, Guo Z, Quick D, Franzusoff A, Greiner JW, Schlom J, Hodge JW.
Vaccination with a Recombinant Saccharomyces cerevisiae Expressing a Tumor Antigen Breaks Immune Tolerance and Elicits Therapeutic Antitumor Responses.
Clin. Cancer Res. 14: 4316-25, 2008.
85)  O'Mahony D, Morris J, Quinn C, Gaol W, Wilson W, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher T, Gulley J, Schlom J, Nussenblatt R, Albert P, Davis T, Lowy I, Petrus M, Waldmann T, Janik J.
A pilot study of cytotoxic T-lymphocyte associated antigen 4 blockade after cancer vaccine failure in patients with advanced malignancy.
Clin Cancer Res. 958-964, 2007.
86)  Mostbock S, Catalfamo M, Tagaya Y, Schlom J, Sabzevari H.
Acquisition of antigen presentasome (APS), an MHC/costimulatory complex, is a checkpoint of memory T-cell homeostasis.
Blood. 109: 2488-95, 2007.
87)  Schlom J, Arlen P, Gulley J.
Cancer vaccines: moving beyond current paradigms.
Clin. Cancer Res. 13: 3776-82, 2007.
88)  Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW.
Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination.
Vaccine. 25: 2085-94, 2007.
89)  Zaharoff D, Rogers C, Hance K, Schlom J, Greiner J.
Chitosan solution enhances the immunoadjuvant properties of GM-CSF.
Vaccine. 25: 8673-86, 2007.
90)  Arlen P, Skarupa L, Pazdur M, Seetharam M, Tsang K, Grosenbach D, Feldman J, Poole D, Litzinger M, Steinberg S, Jones E, Chen C, Marte J, Parnes H, Wright J, Dahut W, Schlom J, Gulley J.
Clinical safety of a viral vector-based prostate cancer vaccine strategy.
J Urol. 1515-20, 2007.
91)  Kudo-Saito C, Wansley E, Gruys M, Wiltrout R, Schlom J, Hodge J.
Combination therapy of an orthotopic renal cell carcinoma model employing intratumoral vector-mediated costimulation and systemic IL-2.
Clin Cancer Res. 1936-1946, 2007.
92)  Arlen P, Madan R, Hodge J, Schlom J, Gulley J.
Combining vaccines with conventional therapies for cancer.
Update Cancer Ther. 2: 33-9, 2007.
93)  Rogers C, Berrigan D, Zaharoff D, Hance K, Patel A, Perkins S, Schlom J, Greiner J, Hursting S.
Energy restriction and exercise differentially enhance components of systemic and mucosal immunity in mice.
J Nutr. 138: 115-22, 2007.
94)  Mostbock S, Vidal S, Schlom J, Sabzevari H.
Enhanced levels of costimulation lead to reduced effector/memory CD8+ T cell functionality.
J Immunol. 3524-34, 2007.
95)  Yokokawa J, Bera T, Palena C, Cereda V, Remondo C, Gulley J, Arlen P, Pastan I, Schlom J, Tsang K.
Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4).
Int. J. Cancer. 595-605, 2007.
96)  Kudo-Saito C, Garnett CT, Wansley EK, Schlom J, Hodge JW.
Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity.
Cancer Immunol Immunother. 56: 1897-910, 2007.
97)  Theoret M, Arlen P, Pazdur M, Dahut W, Schlom J, Gulley J.
Phase I trial of an enhanced prostate-specific antigen-based vaccine with anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
Clin Genitourin Cancer. 5: 347-50, 2007.
98)  Fang L, Holford NH, Hinkle G, Cao X, Xiao JJ, Bloomston M, Gibbs S, Saif OH, Dalton JT, Chan KK, Schlom J, Martin EW, Sun D.
Population Pharmacokinetics of Humanized Monoclonal Antibody HuCC49{triangleup}CH2 and Murine Antibody CC49 in Colorectal Cancer Patients.
J Clin Pharmacol. 47: 227-37, 2007.
99)  Arlen PM, Gulley JL, Madan RA, Hodge JW, Schlom J.
Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.
Crit. Rev. Immunol. 27: 451-62, 2007.
100)  Schlom J, Gulley J, Arlen P.
Role of vaccine therapy in cancer: biology and practice.
Curr Oncol. 14: 238-245, 2007.
101)  Sharp HJ, Wansley EK, Garnett CT, Chakraborty M, Camphausen K, Schlom J, Hodge JW.
Synergistic antitumor activity of immune strategies combined with radiation.
Front. Biosci. 12: 4900-10, 2007.
102)  Zeytin H, Reali E, Zaharoff D, Rogers C, Schlom J, Greiner J.
Targeted delivery of murine interferon-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity.
J Interferon and Cytokine Res. 28: 73-87, 2007.
103)  Chakraborty M, Schlom J, Hodge JW.
The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses.
Cancer Immunol. Immunother. 56: 1471-84, 2007.
104)  Palena C, Polev D, Tsang K, Fernanco R, Litzinger M, Krukovskaya L, Baranova A, Kozlov A, Schlom J.
The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell mediated cancer immunotherapy.
Clin Cancer Res. 13: 2471-2478, 2007.
105)  Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C.
The IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
Blood. 110: 3192-201, 2007.
106)  Hodge J, Schlom J, Abrams S.
Kufe D, Bast Jr R, Hair W, eds.
Vaccines and Immunostimulants. In: Holland - Frei Cancer Medicine. Volume 7th Edition.
Hamilton, Ontario: BC Decker Inc.; 2006. p. 786-801 [Book Chapter]
107)  Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, Schlom J, Kaufman HL.
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
Vaccine. 24: 4975-4986, 2006.
108)  Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J, Steinberg SM, Jones E, Chen C, Marte J, Schlom J, Dahut W.
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Clin Cancer Res. 12: 1260-9, 2006.
109)  Palena C, Abrams SI, Schlom J, Hodge JW.
Cancer vaccines: preclinical studies and novel strategies.
Adv. Cancer Res. 95: 115-45, 2006.
110)  Gelbard A, Garnett CT, Abrams SI, Patel V, Gutkind JS, Palena C, Tsang KY, Schlom J, Hodge JW.
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Clin Cancer Res. 12: 1897-905, 2006.
111)  Hodge J, Greiner J, Tsang K, Sabzevari H, Kudo-Saito C, Grosenbach D, Gulley J, Arlen P, Marshall J, Panicali D, Schlom J.
Costimulatory molecules as adjuvants for immunotherapy.
Front Biosci. 11: 788-803, 2006.
112)  Kaufman HL, Cohen S, Cheung K, DeRaffele G, Mitcham J, Moroziewicz D, Schlom J, Hesdorffer C.
Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors.
Hum Gene Ther. 17: 239-44, 2006.
113)  Chinn PC, Morena RA, Santoro DA, Kazules T, Kashmiri SV, Schlom J, Hanna N, Braslawsky G.
Pharmacokinetics and Tumor Localization of (111)In-Labeled HuCC49DeltaC(H)2 in BALB/c Mice and Athymic Murine Colon Carcinoma Xenograft.
Cancer Biother Radiopharm. 21: 106-16, 2006.
114)  Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, K Wansley E, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ.
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.
J Exp Med. 203: 1259-71, 2006.
115)  Garnett CT, Greiner JW, Tsang K, Kudo-Saito C, Grosenbach DW, Chakraborty M, Gulley JL, Arlen PM, Schlom J, Hodge JW.
TRICOM vector-based cancer vaccines.
Curr Pharm Des. 12: 351-61, 2006.
116)  Tsang KY, Palena C, Yokokawa J, Arlen PM, Gulley JL, Mazzara GP, Gritz L, Yafal AG, Ogueta S, Greenhalgh P, Manson K, Panicali D, Schlom J.
Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Clin Cancer Res. 11: 1597-607, 2005.
117)  Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Ménard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W.
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Clin Cancer Res. 11: 3353-62, 2005.
118)  Reali E, Canter D, Zeytin H, Schlom J, Greiner JW.
Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms.
Vaccine. 23: 2909-21, 2005.
119)  Kudo-Saito C, Schlom J, Hodge JW.
Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Clin Cancer Res. 11: 2416-26, 2005.
120)  Gonzales NR, De Pascalis R, Schlom J, Kashmiri SV.
Minimizing the immunogenicity of antibodies for clinical application.
Tumour Biol. 26: 31-43, 2005.
121)  Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK.
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
Clin Cancer Res. 11: 3017-24, 2005.
122)  Kashmiri SV, De Pascalis R, Gonzales NR, Schlom J.
SDR grafting-a new approach to antibody humanization.
Methods. 36: 25-34, 2005.
123)  Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang K, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J, Fox E, Odogwu L, Park S, Panicali D, Schlom J.
A phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM (B7-1/ICAM-1/LFA-3) alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without GM-CSF, in patients with CEA-expressing carcinomas.
J Clin Oncol. 23: 720-31, 2005.
124)  Palena C, Foon KA, Panicali D, Yafal AG, Chinsangaram J, Hodge JW, Schlom J, Tsang KY.
A potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.
Blood. 106: 3515-3523, 2005.
125)  Arlen PM, Gulley JL, Todd N, Lieberman R, Steinberg SM, Morin S, Bastian A, Marte J, Tsang KY, Beetham P, Grosenbach DW, Schlom J, Dahut W.
Antiandrogen, vaccine and combination therapy in nonmetastatic hormone refractory prostate cancer patients.
J. Urol. 174: 539-46, 2005.
126)  Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I, Schlom J, Tsang KY.
Identification of novel human cytotoxic T lymphocyte epitopes and their agonist epitopes of mesothelin.
Clin Cancer Res. 11: 6342-51, 2005.
127)  Yang S, Tsang KY, Schlom J.
Induction of higher avidity human CTL by vector-mediated enhanced costimulation of antigen-presenting cells.
Clin Cancer Res. 11: 5603-15, 2005.
128)  Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H.
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.
Blood. 105: 2862-8, 2005.
129)  Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J.
Multiple costimulatory modalities enhance CTL avidity.
J. Immunol. 174: 5994-6004, 2005.
130)  Zhou J, Tagaya Y, Tolouei-Semnani R, Schlom J, Sabzevari H.
Physiological relevance of Antigen Presentosome (APS), an acquired MHC/costimulatory complex, in the sustained activation of CD4+ T cells in the absence of APCs.
Blood. 105: 3238-46, 2005.
131)  Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW.
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Clin Cancer Res. 11: 4533-4544, 2005.
132)  Yang S, Hodge JW, Grosenbach DW, Schlom J.
Vaccines with enhanced costimulation maintain high avidity memory CTL.
J. Immunol. 175: 3715-23, 2005.
133)  Tsang KY, Palena C, Gulley J, Arlen P, Schlom J.
A human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1.
Clin Cancer Res. 10(6): 2139-2149, 2004.
134)  Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, Hodge JW, Schlom J, Sabzevari H.
Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of CD54 in target cells; implications for intratumoral vaccine therapy.
Cancer Gene Ther. 11: 665-80, 2004.
135)  Zeytin HE, Patel AC, Rogers CJ, Canter D, Hursting SD, Schlom J, Greiner JW.
Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (Celecoxib) elicits anti-tumor immunity and long-term survival in CEA.Tg/min mice.
Cancer Res. 64 (10): 3668-3678, 2004.
136)  Schlom J, Palena C, Greiner JW, Tsang KY, Grosenbach DW, Sabzevari H, Gulley JL, Arlen PM, Kass E, Hodge JW.
Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation.
Dev Biol (Basel). 116: 27-47, 2004.
137)  Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW.
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine mediated T-cell killing.
Cancer Res. 64 (12): 4328-4337, 2004.
138)  Palena C, Zhu M, Schlom J, Tsang KY.
Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells.
Blood. 104 (1): 192-199, 2004.
139)  Belardelli F, Ferrantini M, Parmiani G, Schlom J, Garaci E.
International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?.
Cancer Res. 64: 6827-30, 2004.
140)  Kudo-Saito C, Schlom J, Hodge JW.
Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.
Clin Cancer Res. 10: 1090-9, 2004.
141)  Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM.
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
J Clin Oncol. 22: 2122-32, 2004.
142)  Milenic D, Garmestani K, Dadachova E, Chappell L, Albert P, Hill D, Schlom J, Brechbiel M.
Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody.
Cancer Biother Radiopharm. 19: 135-47, 2004.
143)  Gonzales NR, Padlan EA, De Pascalis R, Schuck P, Schlom J, Kashmiri SV.
SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.
Mol Immunol. 41: 863-72, 2004.
144)  Garnett CT, Palena C, Chakraborty M, Chakarborty M, Tsang KY, Schlom J, Hodge JW.
Sub-lethal irradiation of human tumor cells modulates phenotype resulting in enhanced illing by CTL.
Cancer Res. 64: 7985-94, 2004.
145)  Arlen PM, Gulley JL, Palena C, Marshall J, Schlom J, Tsang KY.
A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1.
J. Immunol. Methods. 279: 183-92, 2003.
146)  Forero A, Meredith RF, Khazaeli MB, Carpenter DM, Shen S, Thornton J, Schlom J, LoBuglio AF.
A novel monoclonal antibody design for radioimmunotherapy.
Cancer Biother. Radiopharm. 18: 751-9, 2003.
147)  Grosenbach DW, Schlom J, Gritz L, Gómez Yafal A, Hodge JW.
A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1, ICAM-1, LFA-3) induces sustained CD4+ and CD8+ T-cell activation, protection from apoptosis, and enhanced cytokine production.
Cell Immunol. 222: 45-57, 2003.
148)  Schlom J, Sabzevari H, Grosenbach DW, Hodge JW.
A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines.
Artif. Cells Blood Substit. Immobil. Biotechnol. 31: 193-228, 2003.
149)  Palena C, Schlom J, Tsang KY.
Differential Gene Expression Profiles in a Human T-cell Line Stimulated with a Tumor-associated Self-peptide versus an Enhancer Agonist Peptide.
Clin Cancer Res. 9: 1616-27, 2003.
150)  Palena C, Arlen P, Zeytin H, Greiner JW, Schlom J, Tsang KY.
Enhanced expression of lymphotactin by CD8(+) T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens.
Cytokine. 24: 128-42, 2003.
151)  Hodge JW, Tsang KY, Poole DJ, Schlom J.
General keynote: vaccine strategies for the therapy of ovarian cancer.
Gynecol Oncol. 88: S97-104; discussion S110-3, 2003.
152)  Morse MA, Nair SK, Mosca PJ, Hobeika AC, Clay TM, Deng Y, Boczkowski D, Proia A, Neidzwiecki D, Clavien PA, Hurwitz HI, Schlom J, Gilboa E, Lyerly HK.
Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA.
Cancer Invest. 21: 341-9, 2003.
153)  De Pascalis R, Gonzales NR, Padlan EA, Schuck P, Batra SK, Schlom J, Kashmiri SV.
In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants.
Clin Cancer Res. 9: 5521-31, 2003.
154)  Gonzales NR, Padlan EA, De Pascalis R, Schuck P, Schlom J, Kashmiri SV.
Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues.
Mol Immunol. 40: 337-49, 2003.
155)  Hodge JW, Poole DJ, Aarts WM, Gómez Yafal A, Gritz L, Schlom J.
Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Cancer Res. 63: 7942-9, 2003.
156)  Oh S, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA.
Selective induction of high avidity CTL by altering the balance of signals from APC.
J Immunol. 170: 2523-30, 2003.
157)  Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.
Vaccine therapy of established tumors in the absence of autoimmunity.
Clin Cancer Res. 9: 1837-49, 2003.
158)  Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, LoBuglio AF.
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
Clin Cancer Res. 8: 2806-11, 2002.
159)  Tatari-Calderone Z, Semnani RT, Nutman TB, Schlom J, Sabzevari H.
Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction.
J Immunol. 169: 6162-9, 2002.
160)  Kennel SJ, Brechbiel MW, Milenic DE, Schlom J, Mirzadeh S.
Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.
Cancer Biother Radiopharm. 17: 219-31, 2002.
161)  Kass ES, Greiner JW, Kantor JA, Tsang KY, Guadagni F, Chen Z, Clark B, De Pascalis R, Schlom J, Van Waes C.
Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer.
Cancer Res. 62: 5049-57, 2002.
162)  De Pascalis R, Iwahashi M, Tamura M, Padlan EA, Gonzales NR, Santos AD, Giuliano M, Schuck P, Schlom J, Kashmiri SV.
Grafting of.
J Immunol. 169: 3076-84, 2002.
163)  Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J.
Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
Clin Cancer Res. 8: 41-53, 2002.
164)  Schmitz J, Reali E, Hodge JW, Patel A, Davis G, Schlom J, Greiner JW.
Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
Cancer Res. 62: 5058-64, 2002.
165)  Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB.
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.
J Immunother. 25: 97-138, 2002.
166)  Milenic DE, Garmestani K, Chappell LL, Dadachova E, Yordanov A, Ma D, Schlom J, Brechbiel MW.
In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.
Nucl. Med. Biol. 29: 431-42, 2002.
167)  Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J.
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
Prostate. 53: 109-17, 2002.
168)  DeNardo GL, Schlom J, Buchsbaum DJ, Meredith RF, O'Donoghue JA, Sgouros G, Humm JL, DeNardo SJ.
Rationales, evidence, and design considerations for fractionated radioimmunotherapy.
Cancer. 94: 1332-48, 2002.
169)  Gonzales NR, Schuck P, Schlom J, Kashmiri SV.
Surface plasmon resonance-based competition assay to assess the sera reactivity of variants of humanized antibodies.
J Immunol Methods. 268: 197-210, 2002.
170)  Morse MA, Nair SK, Boczkowski D, Tyler D, Hurwitz HI, Proia A, Clay TM, Schlom J, Gilboa E, Lyerly HK.
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.
Int. J. Gastrointest. Cancer. 32: 1-6, 2002.
171)  Greiner JW, Zeytin H, Anver MR, Schlom J.
Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
Cancer Res. 62: 6944-51, 2002.
172)  Hodge JW, Grosenbach DW, Schlom J.
Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity.
Cancer Detect. Prev. 26: 275-91, 2002.
173)  Aarts WM, Schlom J, Hodge JW.
Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Cancer Res. 62: 5770-7, 2002.
174)  Sabzevari H, Kantor J, Jaigirdar A, Tagaya Y, Naramura M, Hodge J, Bernon J, Schlom J.
Acquisition of CD80 (B7-1) by T cells.
J Immunol. 166: 2505-13, 2001.
175)  Simon RM, Steinberg SM, Hamilton M, Hildesheim A, Khleif S, Kwak LW, Mackall CL, Schlom J, Topalian SL, Berzofsky JA.
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
J. Clin. Oncol. 19: 1848-54, 2001.
176)  Guadagni F, Kantor J, Aloe S, Carone MD, Spila A, D'Alessandro R, Abbolito MR, Cosimelli M, Graziano F, Carboni F, Carlini S, Perri P, Sciarretta F, Greiner JW, Kashmiri SV, Steinberg SM, Roselli M, Schlom J.
Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Cancer Res. 61: 2523-32, 2001.
177)  Kashmiri SV, Iwahashi M, Tamura M, Padlan EA, Milenic DE, Schlom J.
Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.
Crit Rev Oncol Hematol. 38: 3-16, 2001.
178)  Zhu M, Terasawa H, Gulley J, Panicali D, Arlen P, Schlom J, Tsang KY.
Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
Cancer Res. 61: 3725-34, 2001.
179)  Shankar P, Schlom J, Hodge JW.
Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3).
Vaccine. 20: 744-55, 2001.
180)  Hodge JW, Grosenbach DW, Rad AN, Giuliano M, Sabzevari H, Schlom J.
Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules.
Vaccine. 19: 3552-67, 2001.
181)  Wallace PK, Tsang KY, Goldstein J, Correale P, Jarry TM, Schlom J, Guyre PM, Ernstoff MS, Fanger MW.
Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I.
J. Immunol. Methods. 248: 183-94, 2001.
182)  Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW.
Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Cancer Res. 61: 206-14, 2001.
183)  Milenic DE, Roselli M, Mirzadeh S, Pippin CG, Gansow OA, Colcher D, Brechbiel MW, Schlom J.
In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates.
Cancer Biother. Radiopharm. 16: 133-46, 2001.
184)  Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin CY, Macey DJ, Austin JM, Kilgore LC, Grizzle WE, Schlom J, LoBuglio AF.
Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.
Cancer Biother Radiopharm. 16: 305-15, 2001.
185)  Grosenbach DW, Barrientos JC, Schlom J, Hodge JW.
Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
Cancer Res. 61: 4497-505, 2001.
186)  Tsang KY, Zhu M, Even J, Gulley J, Arlen P, Schlom J.
The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
Cancer Res. 61: 7568-76, 2001.
187)  von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, Weiner LM.
The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
Clin Cancer Res. 7: 1181-91, 2001.
188)  Rad AN, Schlom J, Hodge JW.
Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors.
Crit. Rev. Oncol. Hematol. 39: 43-57, 2001.
189)  Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW.
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
Clin Cancer Res. 6: 1632-8, 2000.
190)  Salazar E, Zaremba S, Arlen PM, Tsang KY, Schlom J.
Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide.
Int. J. Cancer. 85: 829-38, 2000.
191)  Kass E, Parker J, Schlom J, Greiner JW.
Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen- presenting cells in regional lymph nodes.
Cytokine. 12: 960-71, 2000.
192)  Hodge JW, Schlom J.
Costimulatory molecules in vaccine design.
Ernst Schering Res. Found. Workshop. 23-52, 2000.
193)  Hodge JW, Rad AN, Grosenbach DW, Sabzevari H, Yafal AG, Gritz L, Schlom J.
Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.
J Natl Cancer Inst. 92: 1228-39, 2000.
194)  Tempero M, Leichner P, Baranowska-Kortylewicz J, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D.
High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
Clin Cancer Res. 6: 3095-102, 2000.
195)  Hörig H, Lee DS, Conkright W, Divito J, Hasson H, LaMare M, Rivera A, Park D, Tine J, Guito K, Tsang KW, Schlom J, Kaufman HL.
Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule.
Cancer Immunol Immunother. 49: 504-14, 2000.
196)  Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P, Tsang KY, Schlom J.
Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
J Clin Oncol. 18: 3964-73, 2000.
197)  von Mehren M, Arlen P, Tsang KY, Rogatko A, Meropol N, Cooper HS, Davey M, McLaughlin S, Schlom J, Weiner LM.
Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas.
Clin Cancer Res. 6: 2219-28, 2000.
198)  Reisfeld RA, Schlom J.
Report of the second annual walker's cay colloqium on cancer vaccines and immunotherapy, March 8-11, 2000.
Int. J. Immunopharmacol. 22: 1009-14, 2000.
199)  Patel SD, Moskalenko M, Tian T, Smith D, McGuinness R, Chen L, Winslow GA, Kashmiri S, Schlom J, Stanners CP, Finer MH, McArthur JG.
T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors.
Cancer Gene Ther. 7: 1127-34, 2000.
200)  Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, Hand PH, Schlom J, Hamilton JM.
The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
Cancer Immunol Immunother. 49: 517-29, 2000.
201)  Freund YR, Mirsalis JC, Fairchild DG, Brune J, Hokama LA, Schindler-Horvat J, Tomaszewski JE, Hodge JW, Schlom J, Kantor JA, Tyson CA, Donohue SJ.
Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity.
Int J Cancer. 85: 508-17, 2000.
202)  Roselli M, Milenic DE, Brechbiel MW, Mirzadeh S, Pippin CG, Gansow OA, Colcher D, Schlom J.
In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts.
Cancer Biother. Radiopharm. 14: 209-20, 1999.
203)  Schlom J, Tsang KY, Kantor JA, Abrams SI, Zaremba S, Greiner J, Hodge JW.
Cancer vaccine development.
Expert Opin Investig Drugs. 7: 1439-52, 1998.
204)  Slavin-Chiorini DC, Kashmiri SV, Lee HS, Milenic DE, Poole DJ, Bernon E, Schlom J, Hand PH.
A CDR-grafted (humanized) domain-deleted antitumor antibody.
Cancer Biother. Radiopharm. 12: 305-16, 1997.
205)  Schlom J, Hodge JW, Palena C, Greiner JW, Tsang KY, Farsaci B, Madan RA, Gulley JL.
Prendergast G, Jaffee E, eds.
Recombinant TRICOM-based therapeutic cancer vaccines: lessons learned. In: Cancer Immunotherapy.
Elsevier; . In Press. [Book Chapter]
206)  Palena C, Schlom J.
Target: Brachyury, a master driver of epithelial-to-mesenchymal transition (EMT). In: Encyclopedia of Cancer Therapeutic Targets; J Marshall, editor.
Springer; . In Press. [Book Chapter]
207)  Schlom J, Palena C, Gulley JL, Greiner JW, Tsang KY, Madan RA, Hodge JW.
Lattime E, Gerson S, eds.
The use of T-cell costimulation to enhance the immunogenicity of tumors. In: Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation. Volume Third Edition.
Elsevier; . In Press. [Book Chapter]
208)  Farsaci B, Kim PS, Hodge JW, Palena C, Gulley JL, Schlom J.
Vaccine therapy and integration with other modalities. In: Targeted Therapies in Oncology; G Giaccone and J-C Soria, eds. Volume Second Edition.
CRC Press; . In Press. [Book Chapter]
Click Here to View Collapsed Bibliography.

This page was last updated on 4/11/2014.